Your browser doesn't support javascript.
loading
A biomarker assay validation approach tailored to the context of use and bioanalytical platform.
Hickford, Elizabeth S; Dejager, Lien; Yuill, Daisy; Kotian, Apoorva; Shankar, Sucharita; Staelens, Ludovicus; Ulrichts, Hans; Lewis, Sion; Louber, Jade; Williams, Amanda; Le Provost, Gabrielle S; Cutler, Paul.
Afiliação
  • Hickford ES; Translational Biomarkers & Bioanalysis, Development Sciences, UCB Biopharma UK, Bath Road, Slough, SL1 3WE, UK.
  • Dejager L; Precision Medicine & Biomarkers, Translational Medicine, UCB Pharma, Chemin du Foriest, B-1420 Braine-l'Alleud, Belgium.
  • Yuill D; Translational Biomarkers & Bioanalysis, Development Sciences, UCB Biopharma UK, Bath Road, Slough, SL1 3WE, UK.
  • Kotian A; Translational Biomarkers & Bioanalysis, Development Sciences, UCB Biopharma UK, Bath Road, Slough, SL1 3WE, UK.
  • Shankar S; Translational Biomarkers & Bioanalysis, Development Sciences, UCB Biopharma UK, Bath Road, Slough, SL1 3WE, UK.
  • Staelens L; Translational Biomarkers & Bioanalysis, Development Sciences, UCB Pharma, Chemin du Foriest, B-1420 Braine l'Alleud, Belgium.
  • Ulrichts H; Translational Biomarkers & Bioanalysis, Development Sciences, UCB Pharma, Chemin du Foriest, B-1420 Braine l'Alleud, Belgium.
  • Lewis S; Employed by UCB Pharma, Belgium or UCB Biopharma UK at the time the work was undertaken.
  • Louber J; Translational Biomarkers & Bioanalysis, Development Sciences, UCB Biopharma UK, Bath Road, Slough, SL1 3WE, UK.
  • Williams A; Translational Biomarkers & Bioanalysis, Development Sciences, UCB Biopharma UK, Bath Road, Slough, SL1 3WE, UK.
  • Le Provost GS; Employed by UCB Pharma, Belgium or UCB Biopharma UK at the time the work was undertaken.
  • Cutler P; Translational Biomarkers & Bioanalysis, Development Sciences, UCB Biopharma UK, Bath Road, Slough, SL1 3WE, UK.
Bioanalysis ; 15(13): 757-771, 2023 Jul.
Article em En | MEDLINE | ID: mdl-37526064
ABSTRACT
It is widely acknowledged by the bioanalytical and biomarker community that biomarker assay validations should be fit-for-purpose depending on the context of use. The challenge is how to consistently apply these principles in teams responsible for measuring a disparate array of biomarkers, often on multiple analytical platforms, at various stages of the drug discovery and development pipeline and across diverse biology focus areas. To drive consistency, while maintaining the necessary flexibility to allow validations to be driven by scientific rationale and taking into consideration the context of use and associated biological and (pre)analytical factors, a framework applicable across biomarker assays was developed. Herein the authors share their perspective to engage in the ongoing conversation around fit-for-purpose biomarker assay validation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Descoberta de Drogas Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Descoberta de Drogas Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido